Literature DB >> 7849087

Recent developments in the molecular genetic understanding of breast cancer.

P Devilee1, E Schuuring, M J van de Vijver, C J Cornelisse.   

Abstract

The molecular genetic characterization of breast cancer has implicated or identified the involvement of at least 10 distinct gene alterations in the genesis or progression of this disease. The genes involved fall into three distinct classes, possibly reflecting their particular function in the tumorigenic process. First, there is a class of genes that is being amplified to various levels in clinically manifest breast cancer, most conspicuously c-neu, c-myc, and cyclin D1. Second, an as-yet unknown number of genes are targets for loss of heterozygosity or allelic imbalance events on a number of different chromosomes. Presumably, this reflects the presence of tumor suppressor genes located on chromosomes 3p, 6q, 16q, 17, and possibly a few additional chromosomes. Finally, at least three genes are implicated to confer heritable predisposition to breast cancer. These include the p53 oncogene on 17p, an as yet unknown gene on 17q, and at least one locus outside these regions. While a number of presently unknown genes will soon be identified and cloned, it is becoming evident from genetic mapping studies that the complexity of gene involvement in breast cancer has not yet seen its very limits. A comprehensive multidisciplinary molecular profiling of a large series of tumors of various histological subtypes may aid in understanding how the different genes may cooperate to cause breast cancer.

Entities:  

Mesh:

Year:  1994        PMID: 7849087     DOI: 10.1615/critrevoncog.v5.i2-3.70

Source DB:  PubMed          Journal:  Crit Rev Oncog        ISSN: 0893-9675


  9 in total

1.  Amplification and overexpression of peroxisome proliferator-activated receptor binding protein (PBP/PPARBP) gene in breast cancer.

Authors:  Y Zhu; C Qi; S Jain; M M Le Beau; R Espinosa; G B Atkins; M A Lazar; A V Yeldandi; M S Rao; J K Reddy
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-14       Impact factor: 11.205

Review 2.  N-Methyl-N-nitrosourea as a mammary carcinogenic agent.

Authors:  Ana I Faustino-Rocha; Rita Ferreira; Paula A Oliveira; Adelina Gama; Mário Ginja
Journal:  Tumour Biol       Date:  2015-09-19

Review 3.  Methods for the molecular analysis of cancer. An overview.

Authors:  Ken Mills
Journal:  Mol Biotechnol       Date:  2003-02       Impact factor: 2.695

4.  A genomewide screen for suppressors of Alu-mediated rearrangements reveals a role for PIF1.

Authors:  Karen M Chisholm; Sarah D Aubert; Krister P Freese; Virginia A Zakian; Mary-Claire King; Piri L Welcsh
Journal:  PLoS One       Date:  2012-02-09       Impact factor: 3.240

5.  Lymph node status as a guide to selection of available prognostic markers in breast cancer: the clinical practice of the future?

Authors:  A Elzagheid; T Kuopio; S Pyrhönen; Y Collan
Journal:  Diagn Pathol       Date:  2006-11-08       Impact factor: 2.644

6.  Cyclin D1 expression during rat mammary tumor development and its potential role in the resistance of the Copenhagen rat.

Authors:  J E Korkola; G A Wood; M C Archer
Journal:  Breast Cancer Res       Date:  1999-10-07       Impact factor: 6.466

7.  Increasing genome instability in adrenocortical carcinoma progression with involvement of chromosomes 3, 9 and X at the adenoma stage.

Authors:  A J Russell; J Sibbald; H Haak; W N Keith; A M McNicol
Journal:  Br J Cancer       Date:  1999-10       Impact factor: 7.640

8.  Loss of heterozygosity in sporadic breast tumours at the BRCA2 locus on chromosome 13q12-q13.

Authors:  A M Cleton-Jansen; N Collins; S R Lakhani; J Weissenbach; P Devilee; C J Cornelisse; M R Stratton
Journal:  Br J Cancer       Date:  1995-11       Impact factor: 7.640

9.  Expression of circadian clock genes in human colorectal adenoma and carcinoma.

Authors:  Tomoyuki Momma; Hirokazu Okayama; Masaru Saitou; Hidekazu Sugeno; Nobuhiro Yoshimoto; Yuji Takebayashi; Shinji Ohki; Seiichi Takenoshita
Journal:  Oncol Lett       Date:  2017-09-04       Impact factor: 2.967

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.